Metabolik sendrom ile ilişkili erektil disfonksiyonun medikal tedavisi

Metabolik sendrom diyabetes mellitus, hipertansiyon, obezite ve dislipedimiye bağlı meydana gelen önemli halk sağlığı sorunlarından birisidir. Genelde kardiyovasküler sağlık açısından dikkate alınması gereken bir durum olarak algılanmasına karşın ürolojik hastalıklar açısından da dikkate alınması gereken bir sorundur. Metabolik sendrom varlığında en sık görülen ürolojik rahatsızlıklardan birisi erektil disfonksiyondur. Metabolik sendromlu kişilerdeki erektil disfonksiyon tedavisinde ilk olarak yaşam tarzının düzeltilmesi ve diyabet, dislipidemi ve hipertansiyon gibi eşlik eden diğer patolojilerin düzeltilmesi gereklidir. Bunlara ek olarak, testosteron replasman tedavisi, aromataz inhibitörleri ve PDE5i'lerinin kullanımı mümkündür. Bu seçeneklerin beklenen faydayı sağlamadığı kişilerde cerrahi tedavi olarak penil protez implantasyonu da uygulanabilmektedir

Treatment of erectile dysfunction related to metabolic syndrome

Metabolic syndrome is one of the major public health problems which happens due to diabetes mellitus, hypertension, obesity and dyslipidemia. Although it is perceived as a condition that should be taken into consideration in terms of cardiovascular health in general, it is a problem that should be taken into account in terms of urological diseases. One of the most common urological disorders in the presence of metabolic syndrome is erectile dysfunction. In the treatment of erectile dysfunction in people with metabolic syndrome, it is first necessary to correct lifestyle and other accompanying pathologies such as diabetes, dyslipidemia and hypertension. In addition, it is possible to use testosterone replacement therapy, aromatase inhibitors and PDE-5i. Penile prosthesis implantation can also be applied as a surgical treatment in those who do not have the expected benefit of these options

PDF

___

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853–78. doi: 10.1210/jc.2008-2291
2. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010;12:157–80.
3. Hammarsten J and Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011;8:483–94. doi: 10.1038/ nrurol.2011.112
4. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J 2009;276:5755–67. doi: 10.1111/j.1742-4658.2009.07305.x
5. Brotman DJ and Girod JP. The metabolic syndrome: a tug-of-war with no winner. Cleve Clin J Med 2002;69:990–4.
6. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 2007;4:348–62. doi: 10.1111/j.1743-6109.2007.00439.x
7. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97:23–8. doi: 10.1111/j.1464-410X.2006.06102.x
8. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 2005;96:13M–18M. doi: 10.1016/j. amjcard.2005.07.005
9. Lee RK, Chughtai B, Te AE, Kaplan SA. Sexual function in men with metabolic syndrome. Urol Clin North Am 2012;39:53–62. doi: 10.1016/j.ucl.2011.09.008
10. Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci 1998;851:311–35.
11. Castro-Fernandez C, Olivares A, Söderlund D, López-Alvarenga JC, Zambrano E, Veldhuis JD, et al. A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropin-releasing hormone-releasable luteinizing hormone in obese men. J Clin Endocrinol Metab 2000;85:4603–10. doi: 10.1210/jc.85.12.4603
12. Rosmond R, Wallerius S, Wanger P, Martin L, Holm G, Björntorp P. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med 2003;254:386–90.
13. Kalyani RR and Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226–34. doi: 10.1097/MED.0b013e32814db856
14. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008;51:741–7. doi: 10.1530/EJE-07-0663
15. Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008;70:358–60. doi: 10.1016/j.mehy.2007.05.020
16. Saenz de Tejada I, Goldstein I. Diabetic penile neuropathy. Urol Clin North Am 1998;15:17–22.
17. Nehra A, Moreland RB. Neurologic erectile dysfunction. Urol Clin North Am 2001;28:289–308.
18. Maiorino MI, Bellastella G, Esposito K. Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl 2015;17:5–10. doi: 10.4103/1008-682X.137687
19. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU Guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism, EAU Male Sexual Dysfunction-Limited Update, March 2017.
20. Cordero A, Bertomeu-Martínez V, Mazón P, Fácila L, BertomeuGonzález V, Conthe P, et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther 2010;28:15–22. doi: 10.1111/j.1755-5922.2009.00123.x
21. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003;2:29–34.
22. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30:10–22. doi: 10.2164/jandrol.108.005215
23. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829–43. doi: 10.1530/EJE-12-0955
24. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975–81. doi: 10.1002/oby.20407
25. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567–76. doi: 10.1111/jsm.12523
26. Musicki B, Bella AJ, Bivalacqua TJ, Davies KP, DiSanto ME, Gonzalez-Cadavid NF, et al. Basic science evidence for the link between erectile dysfunction and cardiometabolic dysfunction. J Sex Med 2015;12:2233–55. doi: 10.1111/jsm.13069
27. Kovac JR, Pastuszak AW, Lamb DJ, Lipshultz LI. Testosterone supplementation therapy in the treatment of patients with metabolic syndrome. Postgrad Med 2014;126:149–56. doi: 10.3810/pgm.2014.11.2843
28. Taylor SR, Meadowcraft LM, Williamson B. Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both. Pharmacotherapy 2015;35:780–92. doi: 10.1002/phar.1623
29. Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013;31:103–25. doi: 10.5534/wjmh.2013.31.2.103
30. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol 2014;65:99–112. doi: 10.1016/j.eururo.2013.08.048
31. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol 2016;5:834–43. doi: 10.21037/tau.2016.07.10
32. Foresta C, Caretta N, Aversa A, Bettocchi C, Corona G, Mariani S, Rossato M. Erectile dysfunction: symptom or disease? J Endocrinol 2004;27:80–95. doi: 10.1007/BF03350917
33. Foresta C, Caretta N, Corona G, Fabbri A, Francavilla S, Jannini E, et al. Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart. Int J Androl 2009;32:198–211. doi: 10.1111/j.1365-2605.2008.00932.x
34. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 2005;7:211–5. doi: 10.1111/j.1463-1326.2004.00397.x
35.Loves S, de Jong J, van Sorge A, Telting D, Tack CJ, Hermus A, et al. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol 2013;169:705–14. doi: 10.1530/EJE-13-0190
36. Schneider T, Gleissner J, Merfort F, Hermanns M, Beneke M, Ulbrich E. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med 2011;8:2904–11. doi: 10.1111/j.1743-6109.2011.02383.x
37. Shabsigh R, Mattern A, REVITALISE Study Group. REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome. J Sex Med 2016;4:e135–44. doi: 10.1016/j.esxm.2016.03.027
38. Maresca L, D’Agostino M, Castaldo L, Vitelli A, Mancini M, Torella G, et al. Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. Monaldi Arch Chest Dis 2013;80:177–83.
39. Ozcan L, Polat EC, Kocaaslan R, Onen E, Otunctemur A, Ozbek E. Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. Andrologia 2017. doi: 10.1111/and.12751
40. Scipioni A, Stefanini S, Santone R, Giorgi M. Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis. Histochem Cell Biol 2005;124:401–7. doi: 10.1007/s00418-005-0057-1
41. Carosa E, Martini P, Brandetti F, Di Stasi SM, Lombardo F, Lenzi A, et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004;6:382–6.
42. Spitzer M, Bhasin S, Travison TG, Davda MN, Stroh H, Basaria S. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013;1:913–8. doi: 10.1111/j.2047- 2927.2013.00131.x
43. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94–9.
44. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658–63. doi: 10.1097/01.ju.0000132389.97804.d7
45. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006;38:61–8. doi: 10.1111/j.1439-0272.2006.00712.x
46. Garcia JA, Sanchez PE, Fraile C, Escovar P. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia 2011;43:293–6. doi: 10.1111/j.1439-0272.2009.00991.x
47. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173:530–2. doi: 10.1097/01.ju.0000149870.36577.05
48. Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571–4. doi: 10.1016/j.urology.2005.09.032
49. Gokkaya SC, Ozden C, Ozdal L, Koyuncu H, Guzel O, Memis A. Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. Scand J Urol Nephrol 2008;42:437–40. doi: 10.1080/00365590801950279
50. Erden Y, Korgalı E, Dundar G, Ayan S, Gokce G, Yildirim S, et al. In-vitro effects of PDE5 inhibitor and statin treatment on the contractile responses of experimental MetS rabbit’s cavernous smooth muscle. Arc Ital Urol Androl 2014;86:33–8. doi: 10.4081/ aiua.2014.1.33